HoLab

Scientist grew up in TAIWAN, studied in USA and work in SWISS. Love immunology, cancer and metabolism.

[Marcos de Lima @DrMarcosdelima]

Congrats, @DrSTANtheMAN !!!

[HoLab @PCHo_Lab]

@YosukeKumamoto @Rutgers_NJMS Congrats! It is well deserved!

[The American Association of Immunologists (AAI) @ImmunologyAAI]

AAI congratulates 2026 Career Awardees for outstanding research and career achievements! Join us to honor them at IMMUNOLOGY2026™. Learn more: https://t.co/ES2PQRUKuM.

[Wei-Le Wang @WeiLeWang1]

Thrilled to announce that our review on IL-22 is out!
This unique cytokine targets non-immune cells to promote gut barrier repair and fight inflammation while connecting mucosal immunity to systemic metabolism — a promising new therapeutic avenue for IBD and beyond.

[Alexis A. Jourdain @jourdainlab]

Very excited to share the published version of our #uridine #CRISPR screen in @NatMetabolism! 🎉

Led by Abigail Strefeler with @Pagliarini_Lab @Zak_Bakes and team!

#NUDT5 #DMQ @DIB_UNIL

🔗 https://t.co/9y4dhnFeMB

🧵1/17

[HoLab @PCHo_Lab]

Thank you for being Lausanne last month! You truly inspire whole generation of immunologists! 2025 Nobel Laureate-Shimon Sakaguchi!

[HoLab @PCHo_Lab]

Check this out!!!

[Science Magazine @ScienceMagazine]

A 2023 @SciImmunology Review contextualizes advances in CAR T cell #cancer immunotherapy, summarizing studies that explore the impact of metabolic stress on this treatment’s efficacy in the tumor microenvironment.

Learn more: https://t.co/gAEBKYWAsA #ScienceMagArchives

[Trends in Immunology @TrendsImmuno]

Mitochondrial lipid metabolism in tumor immunosurveillance and evasion https://t.co/yjZBN0VD2D #immunology

[Cancer Discovery @CD_AACR]

PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Anti-Tumor Immunity against Liver Cancer and Liver Metastasis - by Sheue-Fen Tzeng, Yi-Ru Yu, Chin-Hsien Tsai, @PCHo_Lab, and colleagues at @Ludwig_Cancer @unil @TaipeiMedicalU https://t.co/Egd8lKv15C

[HoLab @PCHo_Lab]

@StanislavDergun I think I know who this handsome scientist is😜

[HoLab @PCHo_Lab]

Congrats for this great work! @jourdainlab

[Alexis A. Jourdain @jourdainlab]

Our updated inventory of genes required for #OXPHOS & findings on #mito defects in #Menieres is now out at @CellReports! 🎉

🧫 New galactose #CRISPR screen
🎯 481 genes required for #OXPHOS
⚙️ #FAM136A in IMS proteostasis
👂 Mito defects in #Menieres

https://t.co/RM6OOK93yK

[Jie Yang @JieYang437]

We're recruiting a postdoc to join my lab at @OxfordOncology & Centre for Immuno-Oncology, @UniofOxford to understand immune regulation in cancer and develop new approaches for cancer prevention and metastasis.

Deadline: 11 August 2025
Apply here: https://t.co/z29ZmDjdGS

[Ludwig Cancer @Ludwig_Cancer]

Researchers led by Ludwig @unil’s Ping-Chih Ho, Xiaoyun Li & Sofie Hedlund Møller report that cancer cells secrete fats that prompt fibroblasts to flip macrophages into a pro-cancer state. Disrupting this process impairs growth in melanoma tumors in mice. https://t.co/igKmZ8hkCg

[HoLab @PCHo_Lab]

Congrats to my superior student #XiaoyunLi and postdoc @sofie_h_moller and all team members. It was a fun journey to work with mycollaborators in Taiwan and Paris. @Ludwig_Cancer @CancerResearch @unil

[Journal of Experimental Medicine @JExpMed]

Li, Møller, Ho et al. @unil show how tumor-derived lipids can induce an IL-6–dependent increased glutamine synthesis pathway in cancer-associated fibroblasts, supporting CAFs ability to promote pro-tumorigenic tumor-associated macrophages. https://t.co/O4mHZAE1HS

[HoLab @PCHo_Lab]

Great work from David!!! A must read.

[David Sancho @SanchoLab]

🙏 @manuelansede por el fantástico artículo!
🙏 @annalaura_mstrn & Iñaki Robles-Vera @Teriyaky_852 por liderar el proyecto
🙏coautores que han hecho posible el trabajo
🙏@FundLaCaixa @CaixaResearch principal financiador
🙏 @AgEInves @CienciaGob @ERC_Research apoyo adicional

[HoLab @PCHo_Lab]

Congrats to Yoshi’s team. Amazing results!

[Waggoner Lab @LabWaggoner]

Microbiota-driven antitumor immunity mediated by dendritic cell migration @Nature
https://t.co/3N4Ii7aQbP

[HoLab @PCHo_Lab]

@NNJarjourPhD @VersitiResearch @MedicalCollege @childrenswi Congrats!!!

[HoLab @PCHo_Lab]

What a amazing 2-photon image from my superb student @Stef_Vil

[Ludwig Cancer @Ludwig_Cancer]

The May 2025 edition of the Ludwig Link is here! Catch up on the latest from Ludwig researchers, including awards, new leadership and a gallery of beautiful (and fascinating) micrographs. Check it out online here https://t.co/qRaKJVyZkX or download the PDF https://t.co/EUTbYcuJHe

[HoLab @PCHo_Lab]

A mist read for liver immunologists!

[Iannacone Lab @iannaconelab]

1/ 🚨 Hot off the press in @NatImmunol: CD4⁺ T cells can license Kupffer cells to rescue dysfunctional CD8⁺ T cells in the liver. Hepatitis B virus (HBV) infection is just the proving ground—this is a paradigm shift in tissue immunity. https://t.co/C6CzH3s34y 🧵(1/11)
2/ Chronic HBV infection was the perfect stress test: intrahepatic CD8⁺ T cells are primed yet quickly stall. How to reignite them has been a major interest of our lab. (2/11)
3/ Pre‑activated helper CD4⁺ T cells solve the puzzle. They skip lymph nodes and head straight to the liver, where they form intimate triads with Kupffer cells (KCs), the resident macrophages patrolling sinusoids. (3/11)
4/ Through CD40L‑CD40 contact, those helpers re‑program KCs—turning tolerant scavengers into potent APC‑like cytokine factories. It’s on‑site immune engineering, not remote coaching. (4/11)
5/ Licensed KCs release a two‑part cocktail:
• IL‑12 expands the helper pool
• IL‑27 wakes up dysfunctional CD8⁺ T cells, restoring effector molecules and metabolic vigor. (5/11)
6/ Dendritic cells? Dispensable. Secondary lymphoid organs? Surgically removed or pharmacologically blocked—help still flows. Immunity can be fabricated in situright inside the parenchyma. (6/11)
7/ Remove KCs and the circuit collapses; block CD40L or IL‑27 and CD8⁺ T cells relapse into lethargy. The essential loop is:
CD4 T cell ➜ KC ➜ IL‑27 ➜CD8 T cell. (7/11)
8/ IL‑27 isn’t just necessary—it’s sufficient. Recombinant IL‑27 revived antiviral CD8⁺ activity in mice and super‑charged HBV‑specific T cells from patients. (8/11)
9/ Why care beyond HBV? Tapping a CD4–IL‑27 axis could be a universal key to re‑arming liver‑resident CD8⁺ T cells against infections and cancer (9/11)
10/ The work reframes “CD4 help”: not a lymph‑node pep talk but an on‑site renovation that overrides local tolerance. Therapeutics that mimic KC licensing could deliver potency where it’s needed and spare the rest of the body. (10/11)
11/ Kudos to Valentina Venzin, Cristian Beccaria, all members of the @IannaconeLab & collaborators for charting this intrahepatic circuit. Expect Kupffer‑cell licensing and IL‑27 to enter conversations on cancer immunotherapy, vaccines and beyond. Thoughts welcome! 🙌
@ImmunoPodcast @profvrr @ERC_Research @EMBO @EMBO_YIP @ArmeniseHarvard
@AIRC_it @MyUniSR @SanRaffaeleMI
(11/11)

[HoLab @PCHo_Lab]

@YosukeKumamoto @VirusesImmunity Wow!